MedTrace Logo

Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia

NCT01150656 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-05-18

No results posted yet for this study

Summary

RATIONALE: Studying the effects of obatoclax mesylate in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of obatoclax mesylate on cancer cells. It may also help doctors identify biomarkers related to cancer.

PURPOSE: This research study is studying obatoclax mesylate in samples from young patients with acute myeloid leukemia.

Conditions

Interventions

GENETIC

gene expression analysis

GENETIC

microarray analysis

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

GENETIC

western blotting

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Carolyn A. Felix, MD · Children's Hospital of Philadelphia

Eligibility

Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150656 on ClinicalTrials.gov